Month: February 2021

TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) — Topicus.com Inc. (TSXV:TOI) in a joint release with Constellation Software Inc. (TSX:CSU) today announced financial results for the TSS Operating Group for the fourth quarter and year ended December 31, 2020. Please note that all amounts referred to in this press release are in Euros unless otherwise stated.The following press release should be read in conjunction with the Annual Consolidated Financial Statements of Constellation Software Netherlands Holding Cooperatief U.A. (the “Coop” or the “Company”) for the year ended December 31, 2020, which we prepared in accordance with International Financial Reporting Standards (“IFRS”) and the Company’s annual Management’s Discussion and Analysis for the year ended December 31, 2020, which can be found on SEDAR at www.sedar.com and on Topicus.com...

Not for distribution to U.S. news wire services or dissemination in the United States.TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) — Helios Fairfax Partners Corporation (TSX: HFPC.U) (“HFP”) announces that it will be releasing its 2020 financial results, as part of its annual report, after the close of markets in Toronto on Friday, March 5, 2021. Given that the transaction creating HFP closed on December 8, 2020, management has determined that it requires the additional time until March 5 to finalize HFP’s 2020 financial results.Helios Fairfax Partners Corporation is an investment holding company whose investment objective is to achieve long-term capital appreciation, while preserving capital, by investing in public and private equity securities and debt instruments in Africa and African businesses or other businesses with customers,...

NASHVILLE, Tenn., Feb. 10, 2021 (GLOBE NEWSWIRE) — Healthcare Realty Trust Incorporated (NYSE:HR) today announced its common stock cash dividend in the amount of $0.3025 per share, payable on March 9, 2021 to stockholders of record on February 22, 2021. This dividend amount reflects an increase from $0.30 per share previously.Healthcare Realty Trust is a real estate investment trust that integrates owning, managing, financing and developing income-producing real estate properties associated primarily with the delivery of outpatient healthcare services throughout the United States. As of December 31, 2020, the Company owned 227 real estate properties in 24 states totaling 16.4 million square feet and was valued at approximately $5.7 billion. The Company provided leasing and property management services to 12.6 million square feet...

BOSTON and ROCKVILLE, Md., Feb. 10, 2021 (GLOBE NEWSWIRE) — Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the closing of its initial public offering of 7,000,052 shares of its common stock on February 8, 2021, as well as the issuance of an additional 1,030,243 shares pursuant to the exercise by the underwriters of their option to purchase additional shares on February 10, 2021, at a public offering price of $19.00 per share. The gross proceeds to Sensei from the two closings, before deducting underwriting discounts and commissions and other offering expenses payable by Sensei, were approximately $152.6 million. All of the shares in the offering were offered by Sensei. Sensei’s common stock is listed on the...

PRESS RELEASE DATED FEBRUARY 10, 2021FILING OF THE DRAFT OFFER DOCUMENT RELATING TO THE SIMPLIFIED TENDER OFFER FOR THE SHARES OFNATIXISinitiated by the companyBPCEPRESS RELEASE RELATING TO THE FILING OF A DRAFT OFFER DOCUMENT PREPARED BY BPCE S.A. TERMS OF THE OFFER:€4.00 per share of Natixis (dividend coupon attached)OFFER PERIOD:20 trading daysThe timetable for the simplified tender offer referred to herein (the “Offer”) will be set out by the Autorité des marchés financiers (the “AMF”) in accordance with provisions of its General Regulation.  AMFThis press release (the “Press Release”) was prepared and made available to the public pursuant to Article 231-16 III of the AMF’s General Regulation.This Offer and the draft Offer document filed today with the AMF (the “Draft Offer Document”) remain subject to AMF’s review.  IMPORTANT NOTICEIn...

COMMUNIQUÉ DU 10 FÉVRIER 2021DÉPÔT DU PROJET DE NOTE D’INFORMATION RELATIVE À L’OFFRE PUBLIQUE D’ACHAT SIMPLIFIÉE VISANT LES ACTIONS DE LA SOCIÉTÉNATIXISinitiée par la sociétéBPCECOMMUNIQUÉ RELATIF AU DÉPÔT D’UN PROJET DE NOTE D’INFORMATION ÉTABLI PAR BPCE S.A. PRIX DE L’OFFRE :4,00 euros par action Natixis (dividende attaché)DURÉE DE L’OFFRE :20 jours de négociationLe calendrier de l’offre publique d’achat simplifiée (l’« Offre ») sera déterminé par l’Autorité des marchés financiers (l’« AMF ») conformément aux dispositions de son règlement général.  AMFLe présent communiqué (le « Communiqué ») a été établi et est diffusé en application des dispositions de l’article 231-16 III du règlement général de l’AMF.            L’Offre et le projet de note d’information déposé ce jour auprès de l’AMF (le « Projet de Note d’Information ») restent...

REDWOOD CITY, Calif., Feb. 10, 2021 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today announced the presentation of data from Cohorts 1-4 of the OPTIC Phase 1 clinical trial of ADVM-022 intravitreal (IVT) injection gene therapy in patients requiring frequent anti-VEGF injections for their wet age-related macular degeneration (AMD). These data were previously presented as part of a corporate update on Saturday, November 14, 2020.Oral Presentation Title: Intravitreal Gene Therapy for Exudative AMD and Diabetic RetinopathyDate and Time: Saturday, February 13, 2021 at 9:30 am ETSession V: Gene Therapy for Exudative AMD and Diabetic RetinopathyPresenter: Arshad M. Khanani, M.D., M.A., Director of Clinical Research, Sierra...

ERYTECH to Present at the 2021 BIO CEO &Investor ConferenceLyon (France) and Cambridge, MA (U.S.), February 10, 2021 – ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced that Chief Executive Officer, Gil Beyen, will present a corporate overview at the 2021 BIO CEO & Investor Conference and participate in select one-on-one investor meetings. The conference will be held virtually this year with all participants joining remotely from February 16  to 18, 2021.Beginning February 16, a pre-recorded presentation by company management will be available foron-demand viewing by registered attendees anytime through March 14th by accessing the BIO CEO Conference portal. For more information...

ERYTECH tiendra une présentation à l’occasiondu BIO CEO & Investor Conference 2021Lyon (France) et Cambridge, MA (États-Unis), le 10 février 2021 – ERYTECH Pharma (Nasdaq & Euronext : ERYP), société biopharmaceutique de stade clinique qui développe des thérapies innovantes en encapsulant des médicaments dans les globules rouges, annonce aujourd’hui que son Directeur Général, Gil Beyen, tiendra une présentation corporate de la société à l’occasion de la BIO CEO & Investor Conference 2021 et participera à des rencontres individuelles avec des investisseurs. La conférence se tiendra virtuellement cette année et tous les participants se joindront à distance du 16 au 18 février 2021.À partir du 16 février, une présentation préenregistrée par le management d’Erytech sera disponible à la demande pour les participants...

(Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Feb. 10, 2021 (GLOBE NEWSWIRE) —Listing market: Euronext GrowthISIN code: FR0010425595About CellectisCellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 21 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving...